Apple files an appeal to overturn the recent iPhone sales ban in China due to its patent infringement of Qualcomm proprietary technology.

Jonah Whanau

2018-12-17 08:43:00 Mon ET

Apple files an appeal to overturn the recent iPhone sales ban in China due to its patent infringement of Qualcomm proprietary technology. This recent ban of some older iPhones 6s to X follows a legal request for an injunction by Qualcomm, which has been locked in an arduous lawsuit with Apple in recent years.

Qualcomm alleges patent violations on specific features that let users reformat the size and appearance of photos with freemium apps on a touch screen. In response, Apple claims that the patents in question cannot cover the latest iOS 12 operating system on all new iPhones Xs, Xs Max, and XR. This patent lawsuit is one legal battle in a much wider rift between Apple and Qualcomm across jurisdictions from Europe to China and South Korea. Mainland China, Hong Kong, and Taiwan are the third-largest market for Apple iPhones. This tripartite region accounts for 20% of $266 billion iPhone sales in the fiscal year as of September 2018.

The Qualcomm injunction may inadvertently induce iPhone users to upgrade their smartphones to iPhones Xs, Xs Max, and XR soon because the older models have become unavailable in the Chinese trifecta. Several Apple upstream suppliers from Foxconn and TSMC to Pegatron and Radiance can benefit much from this complex chemistry.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

President Trump allows most JFK files to be released to the general public.

James Campbell

2017-09-25 09:42:00 Monday ET

President Trump allows most JFK files to be released to the general public.

President Trump has allowed most JFK files to be released to the general public. This batch of documents reveals many details of the assassination of Presid

+See More

Jared Diamond delves into how some societies fail, succeed, and revive in global human history.

Becky Berkman

2023-08-28 08:26:00 Monday ET

Jared Diamond delves into how some societies fail, succeed, and revive in global human history.

Jared Diamond delves into how some societies fail, succeed, and revive in global human history. Jared Diamond (2004)   Collapse: how societies

+See More

The bank-credit-card model and fintech platforms have adapted well to the recent digitization of cashless finance.

Daphne Basel

2023-11-30 08:29:00 Thursday ET

The bank-credit-card model and fintech platforms have adapted well to the recent digitization of cashless finance.

In addition to the OECD bank-credit-card model and Chinese online payment platforms, the open-payments gateways of UPI in India and Pix in Brazil have adapt

+See More

President Trump blames the Federal Reserve for its *crazy tight* interest rate hike.

Becky Berkman

2018-10-13 10:44:00 Saturday ET

President Trump blames the Federal Reserve for its *crazy tight* interest rate hike.

Dow Jones tumbles 3% or 831 points while NASDAQ tanks 4%, and this negative investor sentiment rips through most European and Asian stock markets in early-O

+See More

AYA free finbuzz podcast channel on YouTube March 2019

Andy Yeh Alpha

2019-03-31 11:40:00 Sunday ET

AYA free finbuzz podcast channel on YouTube March 2019

AYA Analytica free finbuzz podcast channel on YouTube March 2019 In this podcast, we discuss several topical issues as of March 2019: (1) Sargent-Wallac

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More